Aneesh Bhim Singhal

Aneesh Bhim Singhal

Auto-generated profile, based on publicly available information

Aneesh Bhim Singhal

Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
ASAneesh B. Singhal
Aneesh B. Singhal
RHRula A. Hajj-Ali
Rula A. Hajj-Ali
MTMehmet A. Topcuoglu
Mehmet A. Topcuoglu
JFJoshua Fok
Joshua Fok
JBJames Bena
James Bena
LCLeonard H. Calabrese
Leonard H. Calabrese
Research from JAMA Neurology — Reversible Cerebral Vasoconstriction Syndromes — Analysis of 139 Cases

1 April 2005 in Stroke
Verified
Journal Article
Closed access
ASAneesh B. Singhal
Aneesh B. Singhal
TBThomas Benner
Thomas Benner
LRLuca Roccatagliata
Luca Roccatagliata
WKWalter J. Koroshetz
Walter J. Koroshetz
PSPamela W. Schaefer
Pamela W. Schaefer
ASA. Gregory Sorensen
A. Gregory Sorensen
Background and Purpose— Therapies that transiently prevent ischemic neuronal death can potentially extend therapeutic time windows for stroke thrombolysis. We conducted a pilot study to investigate the effects of high-flow oxygen in acute ischemic stroke. Methods— We randomized patients with acute stroke (<12 hours) and perfusion-diffusion “mismatch” on magnetic resonance imaging (MRI) to high-flow oxygen therapy via facemask for 8 hours (n=9) or room air (controls, n=7). Stroke scale scores and MRI scans were obtained at baseline, 4 hours, 24 hours, 1 week, and 3 months. Clinical deficits and MR abnormalities were compared between groups. Results— Stroke scale scores were similar at baseline, tended to improve at 4 hours (during therapy) and 1 week, and significantly improved at 24 hours in hyperoxia-treated patients. There was no significant difference at 3 months. Mean (±SD) relative diffusion MRI lesion volumes were significantly reduced in hyperoxia-treated patients at 4 hours (87.8±22% versus 149.1±41%; P =0.004) but not subsequent time points. The percentage of MRI voxels improving from baseline “ischemic” to 4-hour “non-ischemic” values tended to be higher in hyperoxia-treated patients. Cerebral blood volume and blood flow within ischemic regions improved with hyperoxia. These “during-therapy” benefits occurred without arterial recanalization. By 24 hours, MRI showed reperfusion and asymptomatic petechial hemorrhages in 50% of hyperoxia-treated patients versus 17% of controls ( P =0.6). Conclusions— High-flow oxygen therapy is associated with a transient improvement of clinical deficits and MRI abnormalities in select patients with acute ischemic stroke. Further studies are warranted to investigate the safety and efficacy of hyperoxia as a stroke therapy.

17 September 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
ASAneesh B. Singhal
Aneesh B. Singhal
JBJosé Biller
José Biller
MEMitchell S. Elkind
Mitchell S. Elkind
HFHeather J. Fullerton
Heather J. Fullerton
EJEdward C. Jauch
Edward C. Jauch
SLSteven R. Levine
Steven R. Levine
Approximately 15% of all ischemic strokes (IS) occur in young adults and adolescents. To date, only limited prior public health and research efforts have specifically addressed stroke in the young. Early diagnosis remains challenging because of the lack of awareness and the relative infrequency of stroke compared with stroke mimics. Moreover, the causes of IS in the young are heterogeneous and can be relatively uncommon, resulting in uncertainties about diagnostic evaluation and cause-specific management. Emerging data have raised public health concerns about the increasing prevalence of traditional vascular risk factors in young individuals, and their potential role in increasing the risk of IS, stroke recurrence, and poststroke mortality. These issues make it important to formulate and enact strategies to increase both awareness and access to resources for young stroke patients, their caregivers and families, and health care professionals. The American Academy of Neurology recently convened an expert panel to develop a consensus document concerning the recognition, evaluation, and management of IS in young adults and adolescents. The report of the consensus panel is presented herein.

1 March 2004 in Archives of Neurology
Verified
Journal Article
Closed access
PDF file
ASAneesh B. Singhal
Aneesh B. Singhal
Case Report from JAMA Neurology — Postpartum Angiopathy With Reversible Posterior Leukoencephalopathy

1 January 2013 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RJRuijun Ji
Ruijun Ji
LSLee H. Schwamm
Lee H. Schwamm
MPMuhammad A. Pervez
Muhammad A. Pervez
ASAneesh B. Singhal
Aneesh B. Singhal
Quiz Ref ID Approximately 10% to 14% of ischemic strokes occur in adults ages 18 to 45 years.1-7 Stroke etiology in this population differs by geographic region and has greater heterogeneity than in older individuals.5,8,9 Even within this population, the etiologic spectrum varies according to study type (hospital based1-3 vs epidemiologic10), the extent and availability of diagnostic evaluation, or the criteria used to ascribe etiology. To our knowledge, data concerning ischemic stroke in young adults in the United States is limited to a few studies published more than a decade ago.2-5 Advances in stroke diagnostic tests, particularly neuroimaging, refinement in classification schema,11 and the advent of thrombolysis and stroke unit care, may have significantly impacted the profile of ischemic stroke in young adults. We studied the diagnosis, management, and outcome of ischemic stroke in young adults admitted to our comprehensive stroke center. A major objective was to determine the yield of diagnostic tests and characterize brain and vascular imaging findings, which, to our knowledge, has not been the focus of prior studies.

8 January 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
ASA. B. Singhal
A. B. Singhal
VCV. S. Caviness
V. S. Caviness
ABA. F. Begleiter
A. F. Begleiter
EME. J. Mark
E. J. Mark
GRG. Rordorf
G. Rordorf
WKW. J. Koroshetz
W. J. Koroshetz
Serotonin (5-hydroxytryptamine) is a potent vasoconstrictor amine. The authors report three patients who developed thunderclap headache, reversible cerebral arterial vasoconstriction, and ischemic strokes (i.e., the Call–Fleming syndrome). The only cause for vasoconstriction was recent exposure to serotonergic drugs in all patients, and to pseudoephedrine in one patient. These cases, and the literature, suggest that the use of serotonin-enhancing drugs can precipitate a cerebrovascular syndrome due to reversible, multifocal arterial narrowing.